ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2)

Clin Adv Hematol Oncol. 2003 Apr;1(4):237.
No abstract available

Publication types

  • Clinical Trial, Phase II

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Clinical Protocols
  • Gefitinib
  • Humans
  • Neoplasm Metastasis
  • Patient Selection
  • Quinazolines / therapeutic use*
  • Receptor, ErbB-2 / biosynthesis*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Quinazolines
  • Receptor, ErbB-2
  • Trastuzumab
  • Gefitinib